<\/p>\n\n\n
Market Access<\/p>\n\n\n
Health-tech, biotech, and medtech innovators have proven solutions \u2014 but no map into the Meridian. Regulatory pathways, distribution networks, clinical evidence, and payor relationships each live in a different silo. That’s how we build \u2014 every market access capability stitched together into one integrated entry.<\/p>\n\n\n\n
<\/p>\n\n\n
Typical Regulatory Timeline Solo<\/p>\n<\/div>\n\n\n\n
Decision-Makers Per Market (MoH, Payors, Systems)<\/p>\n<\/div>\n\n\n\n
Shortcuts Without On-Ground Experience<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n
<\/p>\n\n\n
Four Capabilities<\/p>\n\n\n
Innovative solutions only reach the Meridian patients when feasibility, regulation, distribution, and clinical evidence are integrated into one market entry. That’s Takamul<\/strong> applied to market access.<\/p>\n\n\n\n \ud83d\udd0d<\/p>\n\n\n\n Feasibility Studies<\/p>\n\n\n Integrated with local market intelligence to deliver a go\/no-go investment recommendation before a single dollar is committed.<\/p>\n\n\n\n Market data + local insight + commercial reality = informed entry decisions<\/p>\n<\/div>\n<\/div>\n\n\n\n \ud83d\udccb<\/p>\n\n\n\n Regulatory Pathways<\/p>\n\n\n Integrated with in-country regulatory relationships to compress timelines.<\/p>\n\n\n\n Dossiers + regulatory relationships + local adaptation = faster approvals<\/p>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n \ud83e\udd1d<\/p>\n\n\n\n Distribution & Commercial Partners<\/p>\n\n\n Integrated with regulatory status and market positioning to build routes-to-market that actually move product.<\/p>\n\n\n\n Partners + channels + deal structure = products on shelves<\/p>\n<\/div>\n<\/div>\n\n\n\n \ud83c\udfe5<\/p>\n\n\n\n Clinical & Payor Pilots<\/p>\n\n\n Integrated with local clinical workflows and reimbursement models to create the evidence that unlocks adoption.<\/p>\n\n\n\n Pilots + evidence + payor buy-in = sustainable adoption<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n <\/p>\n\n\n Integrated Impact<\/p>\n\n\n Each innovator type gets market access capabilities integrated into their specific context \u2014 not a generic advisory retainer.<\/p>\n\n\n\n \ud83d\udcbb<\/p>\n<\/div>\n\n\n\n Health-Tech & Digital Health<\/p>\n\n\n Regulatory pathways for software-as-medical-device, payor pilot design for digital therapeutics, and distribution through health system IT procurement \u2014 integrated with clinical evidence generation to move from pilot to national scale.<\/p>\n<\/div>\n<\/div>\n\n\n\n \ud83e\uddec<\/p>\n<\/div>\n\n\n\n Biotech & Pharmaceuticals<\/p>\n\n\n Dossier remediation, GCC harmonisation, and SFDA\/MOHAP submissions \u2014 integrated with commercial partner identification and outcomes-based contracting to build market presence from registration through reimbursement.<\/p>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n \ud83d\udd2c<\/p>\n<\/div>\n\n\n\n MedTech & Devices<\/p>\n\n\n Hospital chain introductions, institutional procurement navigation, and clinical pilot design \u2014 integrated with local entity setup and after-sales support models to create sustainable commercial operations.<\/p>\n<\/div>\n<\/div>\n\n\n\n \ud83e\uddea<\/p>\n<\/div>\n\n\n\n Diagnostics & Lab Solutions<\/p>\n\n\n Feasibility studies for lab infrastructure, regulatory submissions for IVDs, and distribution partner vetting \u2014 integrated with public health programme alignment to position diagnostics as part of national health system priorities.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n <\/p>\n\n\n How We Work<\/p>\n\n\n We don’t advise from a distance. We become your in-market commercial team \u2014 feasibility, regulatory, distribution, clinical pilots, all stitched together under one integrated engagement. You focus on the innovation. We deliver the market.<\/p>\n\n\n\n \ud83d\udd17<\/p>\n<\/div>\n\n\n\n Differentiator 01<\/p>\n\n\n Feasibility, regulatory, distribution, and evidence generation under one engagement \u2014 no handoffs, no coordination tax, no gaps between workstreams.<\/p>\n<\/div>\n<\/div>\n\n\n\n \u27f6<\/p>\n<\/div>\n\n\n\n Differentiator 02<\/p>\n\n\n Our commercial model aligns with yours \u2014 we succeed when you launch, scale, and sustain. Not when we deliver a report.<\/p>\n<\/div>\n<\/div>\n\n\n\n \ud83c\udf10<\/p>\n<\/div>\n\n\n\n Differentiator 03<\/p>\n\n\n Partners embedded across KSA, UAE, East Africa, West Africa, and South Asia \u2014 with the regulatory relationships and ministry access that only come from being on the ground.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n <\/p>\n\n\n Our Proof \u00b7 Innovator Market Access<\/p>\n\n\n Three innovators. One playbook. Different sectors, different geographies \u2014 the same path: feasibility, regulatory and funding, distribution, then scale.<\/p>\n\n\n\n MedTech \u00b7 India \u2192 Sub-Saharan Africa<\/p>\n\n\n Strong product, no Africa channel, no donor funding access. AMRA mapped donor funding routes, structured the case, negotiated distribution into Sub-Saharan markets, and stayed engaged through the revenue ramp.<\/p>\n\n\n\n Now \u2014 Scale & Revenue: multi-country presence with recurring donor-funded revenue.<\/p>\n<\/div>\n<\/div>\n\n\n\n HealthTech \u00b7 Asia \u2192 Saudi Arabia<\/p>\n\n\n Proven in Asia, no KSA presence. AMRA diagnosed the opportunity, structured the regulatory and partner pathway, and brokered hospital-chain introductions.<\/p>\n\n\n\n Now \u2014 Distribution: active KSA hospital deployment with a growing GCC pipeline.<\/p>\n<\/div>\n<\/div>\n\n\n\n HealthTech \u00b7 United Arab Emirates<\/p>\n\n\n Strong methodology, needed an anchor partnership. AMRA diagnosed UAE health-system fit and structured a partnership with a major UAE telecom, embedding analytics into a broader health-data offering.<\/p>\n\n\n\n Now \u2014 Regulatory & Funding: established in UAE via telecom partnership, first hospital deployments in pathway.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n <\/p>\n\n\n Ready to Enter the Meridian<\/p>\n\n\n Partner with AMRA to integrate feasibility, regulation, distribution, and clinical evidence into one complete market entry \u2014 from first assessment to first patient.<\/p>\n\n\n\nPre-entry market sizing, commercial pricing, and operational supply assessment<\/h3>\n\n\n\n
SFDA, MOHAP, and DOH submissions, dossier remediation, GCC harmonisation, and fast-track routes<\/h3>\n\n\n\n
Distributor identification, hospital chain introductions, commercial deal structuring, and local entity setup<\/h3>\n\n\n\n
Pilot design, real-world evidence generation, outcomes-based contracting, and reference-site case studies<\/h3>\n\n\n\n
Integrated Impact Across Every Innovator<\/h2>\n\n\n\n
From pilot to national scale<\/h3>\n\n\n\n
From registration through reimbursement<\/h3>\n\n\n\n
Sustainable commercial operations, not one-off sales<\/h3>\n\n\n\n
Part of national health system priorities<\/h3>\n\n\n\n
Your On-the-Ground Commercial Team<\/h2>\n\n\n\n
One Team, Not Five Vendors<\/h3>\n\n\n\n
Success-Based, Not Retainer-Based<\/h3>\n\n\n\n
Meridian-Native, Not Fly-In<\/h3>\n\n\n\n
Lifecycle Market Access — From Entry to Scale<\/h2>\n\n\n\n
Neonatal CPAP & resuscitation portfolio<\/h3>\n\n\n\n
Real-time location systems for hospitals<\/h3>\n\n\n\n
Clinical costing & analytics platform<\/h3>\n\n\n\n
Ready to Take Your Innovation Into the Meridian?<\/h2>\n\n\n\n